Publications by authors named "Ihor Bondarenko"
Purpose: Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1.
View Article and Find Full Text PDFArticle Synopsis
- AS1402 is an immunoglobulin G1 antibody targeting the MUC1 antigen, commonly found in breast tumors, and the study aimed to assess its effectiveness alongside letrozole, a hormone therapy for breast cancer.
- A total of 110 hormone receptor-positive breast cancer patients were split into two groups: one received letrozole alone, and the other received letrozole plus AS1402; however, the trial was halted early due to poorer outcomes in the combination group.
- The final results showed no significant benefit from adding AS1402 to letrozole, suggesting that alternative strategies to inhibit estrogen receptors may be more effective, and genetic variations in certain receptors did not predict treatment success.